Back

Efficacy and safety of various doses of the new dual endothelin receptor antagonist aprocitentan in the treatment of hypertension

31 August 2019 (09:54 - 10:12)
Organised by:
Congress Presentation Part of: Drug treatment in hypertension - New insights Treatment ESC Premium Access ESC Congress 2019

About the speaker

Photo
Ms Parisa Danaietash

Idorsia Pharmaceuticals, Allschwil (Switzerland)

3 More presentations in this session

Presentation thumbnail
State of the Art - Drug treatment in hypertension: unmet needs
Professor B. Williams (London, GB)
Slides Video
Presentation thumbnail
Can anti-hypertensive thiazide diuretics also reduce fragility fracture risk?
Doctor J. Sousa (Porto, PT)
Abstract Slides Video
Presentation thumbnail
New targets for blood pressure lowering drugs
Professor G. Parati (Milan, IT)

Access the full session

Session thumbnail
Drug treatment in hypertension - New insights

The Event

Event poster

ESC Congress 2019

31 August 2019 09:54 CET
You may be interested in
thumbnail
Congress Presentation
Dual endothelin antagonists in hypertension
30 August 2025
thumbnail
Congress Presentation
Selexipag dosing and titration in the first 500 patients enrolled in SPHERE (SelexiPag: tHe UsErs dRug rEgistry)
2 September 2019
thumbnail
Congress Presentation
Efficacy & tolerability of bisoprolol in comparison to metoprolol in Indian patients with stage-1 hypertension: multicentre, parallel group, open labelled, randomised noninferiority clinical study
27 August 2021
thumbnail
Congress Presentation
Safety and effectiveness of edoxaban in a real-world clinical setting: Two-year follow-up of the ETNA-AF-Europe study
25 April 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources